Toxicity and Dermatokinetic Analysis of Ibrutinib in Human Skin Models

• Main Authors: Maria Victória Souto-Silva (Author), Elizabete C. I. Bispo (Author), Lucas F. F. Albuquerque (Author), Stefhani Barcelos (Author), Emãnuella M. Garcez (Author), Luana S. Quilici (Author), Florêncio Figueiredo Cavalcanti Neto (Author), Eliza Carla Barroso Duarte (Author), Jankerle N. Boeloni (Author), Felipe Saldanha-Araujo (Author), Guilherme M. Gelfuso (Author), Juliana Lott Carvalho (Author)
• Format: Book
• Published: MDPI AG, 2024-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

<b>Background/Objectives:</b> Ibrutinib (IBR) is a tyrosine kinase inhibitor under investigation in preclinical and clinical settings as an alternative treatment for melanoma. Nevertheless, the limited oral bioavailability of IBR and the need for high doses of the drug to kill melanoma c...